ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-32C13009
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2023
BUY CHAPTERS

Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2025

Code: QYRE-Auto-32C13009
Report
January 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novo Nordisk
Astrazeneca plc
Eli Lily
GSK
Sanofi
Bristol–Myers Squibb
Abbott Laboratories

Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size

The global market for Glucagon-like peptide 1 (GLP-1)-based Therapies was valued at US$ 5931 million in the year 2024 and is projected to reach a revised size of US$ 7931 million by 2031, growing at a CAGR of 4.3% during the forecast period.

Glucagon-like peptide 1 (GLP-1)-based Therapies Market

Glucagon-like peptide 1 (GLP-1)-based Therapies Market

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Glucagon-like peptide 1 (GLP-1)-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon-like peptide 1 (GLP-1)-based Therapies.
The Glucagon-like peptide 1 (GLP-1)-based Therapies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Glucagon-like peptide 1 (GLP-1)-based Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies Market Report

Report Metric Details
Report Name Glucagon-like peptide 1 (GLP-1)-based Therapies Market
Accounted market size in year US$ 5931 million
Forecasted market size in 2031 US$ 7931 million
CAGR 4.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Pharmacy
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Abbott Laboratories
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Glucagon-like peptide 1 (GLP-1)-based Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Glucagon-like peptide 1 (GLP-1)-based Therapies Market growing?

Ans: The Glucagon-like peptide 1 (GLP-1)-based Therapies Market witnessing a CAGR of 4.3% during the forecast period 2025-2031.

What is the Glucagon-like peptide 1 (GLP-1)-based Therapies Market size in 2031?

Ans: The Glucagon-like peptide 1 (GLP-1)-based Therapies Market size in 2031 will be US$ 7931 million.

Who are the main players in the Glucagon-like peptide 1 (GLP-1)-based Therapies Market report?

Ans: The main players in the Glucagon-like peptide 1 (GLP-1)-based Therapies Market are Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Abbott Laboratories

What are the Application segmentation covered in the Glucagon-like peptide 1 (GLP-1)-based Therapies Market report?

Ans: The Applications covered in the Glucagon-like peptide 1 (GLP-1)-based Therapies Market report are Hospital, Pharmacy

What are the Type segmentation covered in the Glucagon-like peptide 1 (GLP-1)-based Therapies Market report?

Ans: The Types covered in the Glucagon-like peptide 1 (GLP-1)-based Therapies Market report are Exenatied, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide

Recommended Reports

GLP-1 Therapies

Related Peptide Drugs

GLP-1 & Diabetes Markets

1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Overview
1.1 Product Definition
1.2 Glucagon-like peptide 1 (GLP-1)-based Therapies by Type
1.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Type (2024 VS 2031)
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Glucagon-like peptide 1 (GLP-1)-based Therapies by Application
1.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Estimates and Forecasts
1.4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2020-2031
1.4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2020-2031
1.4.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competition by Manufacturers
2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2020-2025)
2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Glucagon-like peptide 1 (GLP-1)-based Therapies, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Product Type & Application
2.7 Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Date of Enter into This Industry
2.8 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
2.8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
2.8.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Scenario by Region
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region: 2020-2031
3.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region: 2020-2025
3.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region: 2026-2031
3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2020-2031
3.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2020-2025
3.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2026-2031
3.4 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.4.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2031)
3.4.3 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.5.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2031)
3.5.3 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Region
3.6.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2031)
3.6.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.7.1 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2031)
3.7.3 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
3.8.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2031)
3.8.3 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2020-2031)
4.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2020-2025)
4.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2026-2031)
4.1.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2020-2031)
4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2020-2031)
4.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2020-2025)
4.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2026-2031)
4.2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2020-2031)
4.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2020-2031)
5 Segment by Application
5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2020-2031)
5.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2020-2025)
5.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2026-2031)
5.1.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2020-2031)
5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2020-2031)
5.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2020-2025)
5.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2026-2031)
5.2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2020-2031)
5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Company Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Eli Lily
6.3.1 Eli Lily Company Information
6.3.2 Eli Lily Description and Business Overview
6.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.3.5 Eli Lily Recent Developments/Updates
6.4 GSK
6.4.1 GSK Company Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Abbott Laboratories
6.7.1 Abbott Laboratories Company Information
6.7.2 Abbott Laboratories Description and Business Overview
6.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
6.7.5 Abbott Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
7.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Production Mode & Process Analysis
7.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Marketing
7.4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Channels
7.4.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors
7.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Customer Analysis
8 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Dynamics
8.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Trends
8.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
8.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
8.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novo Nordisk
Astrazeneca plc
Eli Lily
GSK
Sanofi
Bristol–Myers Squibb
Abbott Laboratories
List of Tables
 Table 1. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Glucagon-like peptide 1 (GLP-1)-based Therapies, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Product Type & Application
 Table 12. Global Key Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K Units)
 Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2020-2025)
 Table 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2026-2031) & (K Units)
 Table 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2026-2031)
 Table 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2020-2025)
 Table 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2026-2031)
 Table 25. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K Units)
 Table 27. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2026-2031) & (K Units)
 Table 28. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Type (2020-2025)
 Table 51. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Type (2026-2031)
 Table 52. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2020-2025)
 Table 53. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2026-2031)
 Table 54. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2020-2025)
 Table 57. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2026-2031)
 Table 58. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Application (2020-2025)
 Table 61. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units) by Application (2026-2031)
 Table 62. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2020-2025)
 Table 63. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2026-2031)
 Table 64. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2020-2025)
 Table 67. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2026-2031)
 Table 68. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Application (2026-2031)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. AstraZeneca Company Information
 Table 76. AstraZeneca Description and Business Overview
 Table 77. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product
 Table 79. AstraZeneca Recent Developments/Updates
 Table 80. Eli Lily Company Information
 Table 81. Eli Lily Description and Business Overview
 Table 82. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product
 Table 84. Eli Lily Recent Developments/Updates
 Table 85. GSK Company Information
 Table 86. GSK Description and Business Overview
 Table 87. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product
 Table 89. GSK Recent Developments/Updates
 Table 90. Sanofi Company Information
 Table 91. Sanofi Description and Business Overview
 Table 92. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product
 Table 94. Sanofi Recent Developments/Updates
 Table 95. Bristol-Myers Squibb Company Information
 Table 96. Bristol-Myers Squibb Description and Business Overview
 Table 97. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product
 Table 99. Bristol-Myers Squibb Recent Developments/Updates
 Table 100. Abbott Laboratories Company Information
 Table 101. Abbott Laboratories Description and Business Overview
 Table 102. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product
 Table 104. Abbott Laboratories Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List
 Table 108. Glucagon-like peptide 1 (GLP-1)-based Therapies Customers List
 Table 109. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Trends
 Table 110. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
 Table 111. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
 Table 112. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
 Figure 2. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type: 2024 & 2031
 Figure 4. Exenatied Product Picture
 Figure 5. Liraglutide Product Picture
 Figure 6. Lixisenatide Product Picture
 Figure 7. Albiglutide Product Picture
 Figure 8. Dulaglutide Product Picture
 Figure 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application: 2024 & 2031
 Figure 11. Hospital
 Figure 12. Pharmacy
 Figure 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (2020-2031) & (K Units)
 Figure 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (US$/Unit) & (2020-2031)
 Figure 17. Glucagon-like peptide 1 (GLP-1)-based Therapies Report Years Considered
 Figure 18. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2024
 Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players: Market Share by Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies in 2024
 Figure 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2020-2031)
 Figure 24. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2020-2031)
 Figure 25. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2020-2031)
 Figure 28. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2020-2031)
 Figure 36. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2020-2031)
 Figure 57. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Application (2020-2031)
 Figure 60. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (US$/Unit) by Application (2020-2031)
 Figure 61. Glucagon-like peptide 1 (GLP-1)-based Therapies Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global GLP 1 Receptor Agonist Drugs Market Research Report 2024
Global GLP 1 Drug Peptide API Market Research Report 2024
Global GLP 1 Receptor Antagonist Market Research Report 2024
Global GLP 1 Drugs Market Research Report 2024
Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025
Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025
GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oral GLP 1 Agonist Market Research Report 2024
Global GLP 1 Agonists for Obesity Market Research Report 2024
Global GLP 1 Agonist Injection Market Research Report 2024
Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024
GLP 1 for Weight Loss Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1RA Therapy Market Research Report 2024
Global GLP 1 based Therapy Market Research Report 2024
Global GLP 1 Injection Market Research Report 2024
Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024
Global GLP 1 Weight Loss Pill Market Research Report 2024
Global GLP 1 Weight Loss Drug Market Research Report 2024
Global GLP 1 Peptide Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions